Sanctuary Advisors LLC Lowers Position in Organon & Co. (NYSE:OGN)

Sanctuary Advisors LLC cut its stake in Organon & Co. (NYSE:OGN) by 0.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 242,055 shares of the company’s stock after selling 1,800 shares during the period. Sanctuary Advisors LLC owned 0.09% of Organon & Co. worth $3,866,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Prospera Private Wealth LLC purchased a new stake in Organon & Co. in the third quarter worth about $25,000. Horizon Bancorp Inc. IN lifted its holdings in Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after buying an additional 1,585 shares during the period. Versant Capital Management Inc lifted its holdings in Organon & Co. by 92.2% in the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after buying an additional 1,324 shares during the period. MassMutual Private Wealth & Trust FSB lifted its holdings in Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after buying an additional 672 shares during the period. Finally, Abich Financial Wealth Management LLC increased its stake in shares of Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after purchasing an additional 2,315 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th. Barclays decreased their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.80.

Organon & Co. Price Performance

Shares of OGN opened at $15.47 on Friday. The company has a market capitalization of $3.98 billion, a P/E ratio of 4.64, a price-to-earnings-growth ratio of 0.85 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a 50 day moving average of $15.36 and a 200 day moving average of $17.28. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, equities research analysts anticipate that Organon & Co. will post 3.78 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.24%. The ex-dividend date is Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.